# Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

> **NCT00048763** · PHASE4 · COMPLETED · sponsor: **Otsuka America Pharmaceutical** · enrollment: 75 (—)

## Conditions studied

- Raynaud's Disease

## Interventions

- **DRUG:** Pletal

## Key facts

- **NCT ID:** NCT00048763
- **Lead sponsor:** Otsuka America Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** 75 (—)
- **Last updated:** 2005-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048763, "Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00048763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*